Bedrijf organiseert conference call en webcast op 15 november 2022 om 13:30 uur GMT / 8:30 uur EST

OXFORD, Engeland–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) zal op dinsdag 15 november 2022, vóór de opening van de Amerikaanse markten, de financiële resultaten voor het derde kwartaal eindigend op 30 september 2022 rapporteren. Het bedrijf zal om 13.30 uur een telefonische vergadering en webcast houden. GMT / 8:30 uur EST, om een bedrijfsupdate te geven en financiële resultaten te beoordelen.

Een webcast van de live-oproep is toegankelijk via het gedeelte ‘Investors and Media’ van de website van het bedrijf op investors.exscientia.ai. U kunt ook toegang krijgen tot de live telefonische vergadering door te bellen naar +1 (888) 330 3292 (VS), +44 203 433 3846 (VK), +1 (646) 960 0857 (Internationaal) en het conferentie-ID in te voeren: 8333895. A replay zal 90 dagen beschikbaar zijn onder “Evenementen en presentaties” in het gedeelte “Investeerders en media” van de Exscientia website.

Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022

Company to host conference call and webcast on November 15, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST

OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST, to provide a business update and review financial results.

A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005320/en/

Contacts

Investors:
Sara Sherman

investors@exscientia.ai

Media:
media@exscientia.ai